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Strengths and limitations of this study
 ► Large sample size.
 ► National cohort study design.
 ► Estimation of absolute risks.
 ► Observational study design.
 ► Possibility of unmeasured confounding.
ABSTRACT
Objectives To estimate the association between 
childhood vaccination and subsequent morbidity and 
mortality by adjusting for environmental and host factors. 
Further, to examine the degree of residual confounding in 
such observational studies.
Design Register-based cohort study including 1 122 929 
Danish children.
Participants All children born in Denmark in the period 
1999–2016 who survived until 16 months of age without 
prior migration followed from 16 months until the first of 
the following: event of interest, migration, 5 years of age or 
31 December 2016.
Main outcome measures Adjusted HRs (aHRs) and 
absolute risks were calculated for the three outcomes: 
mortality, hospitalisation for infection and asthma using 
register data on deaths, specific hospital contacts and 
dispensed prescribed medication. The exposure was the 
combination of the routine vaccines against diphteria–
tetanus–pertussis–polio–Haemophilus influenzae type b 
and measles–mumps–rubella (DTP and MMR in short) 
administered in early childhood. Hospitalisation due to 
accidents was analysed as a negative control outcome to 
examine residual confounding.
Results Children with 3DTP+MMR had a lower hazard of 
mortality than the reference group with 3DTP, adjusted HR 
(aHR)=0.45 (95% CI: 0.35 to 0.57), whereas the children 
with 1 or 2 DTP had higher hazards of dying, aHR=1.55 
(95% CI: 1.14 to 2.13) and aHR=1.96 (95% CI: 1.34 to 
2.89). The vaccination group 3DTP+MMR was associated 
with a reduced hazard of asthma aHR=0.94 (95% CI: 0.92 
to 0.96). Also, the vaccination group 3DTP+MMR was 
associated with a reduced hazard of hospitalisation due 
to accidents, aHR=0.83 (0.80 to 0.85) compared with the 
reference group with 3 DTP.
Conclusions The results suggested a beneficial impact 
of MMR on under-five mortality but did not support the 
hypothesis that DTP is detrimental, since the group 
of children with fewer DTP vaccinations experienced 
increased mortality. The results of the study may to 
some degree be prone to residual confounding since an 
unexpected association between MMR vaccination and 
hospitalisation for accidents was observed.
InTRODuCTIOn
Studies suggest that some of the vaccines 
routinely administered in early childhood 
may affect the risk of illness and death from 
conditions other than the targeted infec-
tious diseases they are designed to prevent. 
The overall hypothesis about the so-called 
non-specific effects of vaccines is that live-at-
tenuated vaccines such as measles-containing 
vaccines may lower subsequent risk, whereas 
subunit vaccines such as the diphtheria–
tetanus–pertussis–polio–Haemophilus influ-
enzae type b (DTP) vaccine may increase risk 
of illness and death from other causes than 
the vaccine target disease.1 2
The beneficial non-specific effects of the 
measles-containing vaccine measles–mumps–
rubella (MMR) were indicated in three 
Danish observational studies.3–5 A study found 
an increased risk of hospitalisation for lower 
airway infection in the small group of chil-
dren who received DTP and MMR simultane-
ously.6 Potential beneficial effects might not 
be restricted to measles-containing vaccines. 
A recent Dutch study found a protective 
effect of receiving further DTP-like vaccines 
on the risk of hospitalisation for infection.7
However, observational vaccine studies 
can be prone to ‘healthy vaccinee bias’. 
Healthy children are more likely to be vacci-
nated so the ‘effects’ of vaccination may be 
explained by general better health in vaccine 
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recipients.8–11 The ability to receive the next vaccine in 
the child vaccination programme indicates good health, 
and it might not matter whether this vaccine is inactivated 
(DTP-like) or live-attenuated (MMR-like). Further, the 
clinical indication for the two vaccine types are different: 
live vaccines as measles-containing vaccines are contra-
indicated in severely immunosuppressed individuals 
since (despite attenuation) the vaccine may replicate 
and infect the recipient.12–14 Individuals who also receive 
live vaccines are probably more immunocompetent than 
those who only receive subunit vaccines. Hence, vacci-
nation status may be a result of good health and not a 
cause. This bias is difficult to accommodate,15 so poten-
tial non-specific effects of vaccines are ideally tested in 
randomised trials. In a recent large randomised trial, we 
studied the potential (a priori thought to be beneficial) 
non-specific effect of another live-attenuated vaccine, 
Bacillus Calmette-Guérin (BCG), on early childhood 
hospitalisation in Denmark, but no non-specific effect 
was found.16
In the present national cohort study, we examine deter-
minants of exposure to all combinations of the MMR and 
DTP vaccines which are scheduled in early childhood in 
the Danish vaccination programme. Since such host and 
environmental factors are likely to confound the rela-
tionship between vaccination exposure and subsequent 
morbidity and mortality, we present the results of adjusted 
analyses. We defined a detailed exposure capturing all 
combinations of DTP and MMR.
MeThODS
The cohort consists of all children liveborn in Denmark 
in the period 1999–2016 who survived until 16 months of 
age without prior migration. They were all followed from 
16 months until the first of the following events: the event 
of interest, death, registered migration out of Denmark, 
5 years of age or 31 December 2016.
Patient and public involvement
The study was based on pseudonymised national registry 
data. Hence no patient and public involvement was 
required. In this register-based study, we had no direct 
patient contact, and no human subjects review board was 
required. This is the usual procedure for register-based 
studies. Data in the public health registers are available 
to researchers on request and subject to permission from 
the authorities.
Registries
The study was based on the Danish health registers17 as 
well as registers from Statistics Denmark18 with infor-
mation on mortality and socioeconomic variables. The 
Central Person Registration (CPR)19 enabled linking of 
data on an individual level. The following health regis-
ters were used: The National Patient Register,20 The 
Register of Medicinal Product Statistics,21 The Medical 
Birth Registry22 and The Danish National Health Service 
Register (NHSR)23 from which the vaccine information 
was obtained. For more details, consult online supple-
mentary table S1.
Vaccination data
The vaccines in the first 15 months of the Danish child 
vaccination programme24 include three administrations 
of the inactivated vaccines, the pentavalent DTP 1 at 3, 
5 and 12 months of age, and one administration of the 
live-attenuated MMR at 15 months of age (see online 
supplementary table S2). We refer to the vaccines as 
DTP and MMR. The DTP used in Denmark is acellular 
(subunit vaccine).
The vaccine information in the NHSR was based on 
invoices from general practitioners. The invoices are 
necessary for the general practitioner to obtain reim-
bursement. This information is collected in NHSR where 
data can be extracted using health service codes of, for 
example, the relevant vaccinations. A complete list of 
the health service codes used in the present study can be 
found in the online supplementary table S3.
NHSR registers services on a weekly basis. We defined 
the vaccinations to take place on the Wednesday of the 
corresponding week. Multiple administrations of the 
same vaccine within the same week were considered as 
one vaccination.
exposure definition: vaccination status
Vaccination status was defined as a time-dependent expo-
sure with the following eight values:
1. 1DTP: One DTP, no MMR
2. 2DTP: Two DTP, no MMR
3. 3DTP: Three DTP, no MMR
4. 1DTP+MMR: One DTP and MMR
5. 2DTP+MMR: Two DTP and MMR
6. 3DTP+MMR: Three DTP and MMR
7. None: neither any DTP nor MMR
8. MMR: MMR, no DTP
The vaccination status for each child changed following 
each additional vaccination after 16 months of age until 
the end of follow-up. The children without any DTP vacci-
nations in groups 7 and 8 are not of primary interest but 
are defined and included for completeness.
Outcomes: mortality and morbidity
Three main outcomes were considered to evaluate the 
non-specific effects of vaccination status on mortality 
and morbidity: (1) mortality, (2) hospitalisation for 
infection and (3) onset of asthma. These outcomes were 
also used in prior studies of potential non-specific effect 
of vaccines.4–6 25 26 Only time to first hospitalisation for 
infection was analysed, and the diagnoses used in the 
definition are stated in the online supplementary table 
S4. The asthma outcome was defined using a customised 
version of an already published and validated algorithm 
for ascertainment of asthma,27 28 but where the event used 
in this paper was defined using only hospitalisations and 
prescriptions between 16 months and 5 years of age.
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Table 1 Absolute and relative numbers of children in the 
study by vaccination status at baseline (16 months of age)
Vaccination status No of children (%)
3DTP* 422 267 (37.60)
1DTP 31 777 (2.83)
2DTP 136 062 (12.12)
1DTP+MMR 12 269 (1.09)
2DTP+MMR 70 040 (6.24)
3DTP+MMR 430 210 (38.31)
None 18 761 (1.67)
MMR 1543 (0.14)
Total 1 122 929 (100.00)
*Reference group in the Results section.
DTP, diphteria–tetanus–pertussis–polio–Haemophilus influenzae 
type b; MMR, measles–mumps–rubella.
Potential confounders
Confounders were defined as potential causes of expo-
sure as well as outcome.29 Twelve potential confounders 
indicating general health status were ascertained at 16 
months of age for each child, and they were all included 
in the adjusted analyses. Five continuous confounders 
were included: number of hospitalisations for infection, 
number of other hospitalisations, number of dispensed 
antibiotics prescriptions, number of other dispensed 
prescriptions and age in days at first discharge to the home 
after birth. Seven categorical confounders were included: 
gender (male/female), presence of chronic disease (yes/
no), presence of atopic disease (yes/no), small for gesta-
tional age (yes/no),30 prematurity (gestational age <37 
weeks), maternal education (<10 years, 10–12 years, >12 
years) and ethnicity (Danish/other) defined by Statistics 
Denmark.18 The last two variables were considered socio-
economic proxies, whereas the remaining variables were 
considered proxies of the host health status.
Definition of children with chronic or atopic disease
Chronic disease or atopic disease may lead to recurrent 
infection and, consequently, postponed vaccinations. 
Children with chronic disease were identified using an 
algorithm using register data on diagnoses of chronic 
disease in relation to hospital admissions.31 Note that the 
definition of chronic disease did not include prescrip-
tions. Children with atopic disease were identified in a 
similar fashion using a validated algorithm,27 28 but in this 
case data on prescribed medication use were also taken 
into account. The disease status was evaluated and fixed 
at 16 months of age.
Statistical methods
The analyses involved estimation of the association 
between vaccination exposure and health status through 
the main outcomes: mortality, hospitalisation for infec-
tion and onset of asthma.
Statistical analyses were performed using Stata/MP 15.1. 
and R version 3.5.1 using the riskRegression package.32
Association between confounders and vaccination group
Note that each potential confounder was included in the 
models irrespective of the magnitude of its marginal asso-
ciation.29 Given the large sample size, the risk of overfit-
ting was minimal as the number of confounders was kept 
relatively low.
Association between vaccination group exposure and outcomes
The mortality outcome was analysed using Cox regres-
sion. The underlying time scale was age with entry at 
16 months of age and exit at 5 years of age. Children 
emigrating out of Denmark before 16 months of age were 
excluded, and children emigrating between 16 months 
and 5 years of age were censored at age of emigration. For 
the categorical variables with missing values, a separate 
category indicating missingness was defined. For each 
outcome, the crude HRs were presented along with the 
HRs obtained after adjustment for the 12 confounders 
(aHR). The proportional-hazards assumption was tested 
using Schoenfeld residuals.
For the two non-mortality outcomes, the cause-specific 
HRs were estimated using a Cox model. However, absolute 
and relative risks are easier to interpret than HRs. To esti-
mate absolute risks of experiencing the events of interest 
(at different landmark time points), the competing event 
of death was accommodated by fitting separate cause-spe-
cific hazards models and then applying the g-formula to 
the results.33 These risks represent average causal effects 
under the hypothesis of no unmeasured confounders.34 
The vaccination-specific absolute risks of experiencing 
the three main outcomes before 5 years of age were esti-
mated from five different landmark times to accommo-
date the time-dependent nature of vaccination status. The 
five landmark times were chosen as 16, 20, 24, 36 and 48 
months of age. The risk predictions from each landmark 
analysis were based on a model fitted to the event-free 
children who survived up to the given landmark age. No 
smoothing of the estimated coefficients across landmark 
models was performed.35
In all analyses the reference group was chosen as the 
group of children with 3 DTP, but no MMR. Children 
with 3 DTPs also represented the reference group in prior 
Danish studies of non-specific effects of vaccination.3
Finally, the potential presence of residual confounding 
was assessed by analysing hospitalisation for accidents 
(injuries) as a negative control outcome.36 These types of 
hospitalisations are not expected to be related to previous 
vaccination history.
ReSulTS
Distribution of vaccination groups
Table 1 shows that the eight different vaccination groups 
defined in the study varied considerably in size. For 
example, children with neither DTP nor MMR at 16 
months of age represented 18 761 children constituting 
only 1.67% of the children in the cohort. On the other 
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Table 3 Crude and adjusted HRs for each outcome. The estimated parameters were HRs. The reference group was the group 
of children with 3DTP, but no MMR
Outcome Mortality Hospitalisation for infection Asthma
Group 
compared 
with 3DTP
Crude HR (95% 
CI)
Adjusted HR (95% 
CI)*
Crude HR (95% 
CI)
Adjusted HR (95% 
CI)*
Crude HR (95% 
CI)
Adjusted HR 
(95% CI)*
1DTP 3.39 (2.33 to 4.93) 1.96 (1.34 to 2.89) 1.06 (1.02 to 1.10) 1.02 (0.98 to 1.06) 0.89 (0.85 to 0.94) 0.87 (0.83 to 0.92)
2DTP 1.90 (1.39 to 2.60) 1.55 (1.14 to 2.13) 1.07 (1.04 to 1.09) 1.04 (1.01 to 1.06) 0.99 (0.96 to 1.03) 0.97 (0.94 to 1.00)
1DTP+MMR 0.37 (0.19 to 0.74) 0.35 (0.18 to 0.70) 0.92 (0.89 to 0.95) 0.95 (0.92 to 0.98) 0.88 (0.84 to 0.92) 0.97 (0.92 to 1.01)
2DTP+MMR 0.50 (0.36 to 0.69) 0.52 (0.38 to 0.72) 0.92 (0.90 to 0.94) 0.94 (0.93 to 0.96) 0.90 (0.88 to 0.92) 0.95 (0.92 to 0.97)
3DTP+MMR 0.40 (0.31 to 0.51) 0.45 (0.35 to 0.57) 0.90 (0.88 to 0.91) 0.93 (0.92 to 0.94) 0.88 (0.86 to 0.90) 0.94 (0.92 to 0.96)
None 2.20 (1.45 to 3.34) 1.51 (0.96 to 2.38) 0.73 (0.70 to 0.76) 0.82 (0.78 to 0.86) 0.49 (0.45 to 0.52) 0.67 (0.63 to 0.72)
MMR 0.86 (0.27 to 2.72) 0.86 (0.27 to 2.74) 0.97 (0.89 to 1.05) 1.03 (0.95 to 1.12) 0.84 (0.75 to 0.94) 0.97 (0.87 to 1.09)
*The parameter estimates corresponding to the confounders are presented in in online supplementary table S7.
DTP, diphteria–tetanus–pertussis–polio–Haemophilus influenzae type b; MMR, measles–mumps–rubella.
Table 2 Absolute number of the primary events mortality, hospitalisation for infection and onset of asthma, and for the last 
two outcomes, the number of competing events (deaths)
Vaccination 
status
No of events by type of outcome
Mortality Hospitalisation for infection Onset of asthma
Primary event
(no competing event) Primary event
Competing event 
(deaths) Primary event
Competing event 
(deaths)
3DTP* 93 21 562 42 14 237 78
1DTP 39 2527 13 1446 27
2DTP 68 8520 23 5335 58
1DTP+MMR 9 3613 6 2254 8
2DTP+MMR 65 19 816 24 12 582 61
3DTP+MMR 304 114 648 142 73 534 257
None 29 1819 10 809 25
MMR <5 534 <5 301 <5
Total† 607–612 173 039 260–265 110 498 514–519
The numbers are shown by vaccination status and in total.
*Reference group in the Results section.
†The number of competing events was lower than the death total, since some deaths took place after the primary event.
DTP, diphteria–tetanus–pertussis–polio–Haemophilus influenzae type b; MMR, measles–mumps–rubella.
hand, the reference group of children with 3 DTPs and 
no MMR represented 422 267 children or 37.60% of 
the children in the cohort. This is important to bear in 
mind before drawing conclusions from the comparisons 
between the different vaccination groups. As mentioned 
in the Methods section, multiple DTP administrations to 
the same child within the same week were considered as 
one vaccination.
In table 2, the number of events is presented for each 
of the three outcomes. The total number of events during 
the study period are presented along with the subtotals 
for each of the vaccination groups. The two non-mortality 
outcomes are prone to the competing risk of death and as 
such the number of competing events is also presented.
effect of vaccination on mortality and morbidity
The analyses examined the association between vaccina-
tion group and mortality, hospitalisation for infection and 
asthma, and the result of confounder adjustment (table 3). 
The aHRs are presented below with 95% CIs in parenthesis 
(the unadjusted HRs can also be found in table 3). No 
serious violations of the proportional hazards assumption 
related to the vaccination status exposure were detected.
Mortality
Children with 1 or 2 DTP only were found to have higher 
hazards of dying than that of the reference group of chil-
dren with 3 DTP: aHR=1.96 (95% CI: 1.34 to 2.89) and 
aHR=1.55 (95% CI: 1.14 to 2.13).
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Children with 3 DTP+MMR were found to have a lower 
hazard of dying compared with that of the 3 DTP group: 
aHR=0.45 (95% CI: 0.35 to 0.57). Based on the CIs, the 
hazards of children with 1, 2 or 3 DTP+MMR were similar.
Hospitalisation for infection
Children with 1 or 2 DTP only were found to have similar 
hazards of being hospitalised for infection compared with 
the reference group of children with 3 DTP: aHR=1.02 
(95% CI: 0.98 to 1.06) and aHR=1.04 (95% CI: 1.01 to 
1.06). Based on the CIs, the hazard in the 1 DTP group 
was not different from that in the 3 DTP groups.
Children with 3 DTP+MMR were found to have a 
slightly lower hazard of being hospitalised for infection 
than that of the 3 DTP group: aHR=0.93 (95% CI: 0.91 to 
0.94) . Based on the CIs, the hazards of children with 1, 2 
or 3 DTP+MMR were similar.
Asthma
Children with 1 or 2 DTP were found to have lower 
hazards of developing asthma than that of the reference 
group of children with 3 DTP: aHR=0.87 (95% CI: 0.83 to 
0.92) and aHR=0.97 (95% CI: 0.94 to 1.00). Based on the 
CIs, the hazard in the 2 DTP group was not significantly 
different from that in the 3 DTP group.
Children with 3 DTP+MMR were found to have a slightly 
lower hazard than that of the 3 DTP group: aHR=0.94 
(95% CI: 0.92 to 0.96). Based on the CIs, the hazards of 
children with 1, 2 or 3 DTP+MMR were similar.
The remaining vaccination groups: no vaccines and MMR only
Two of the smallest vaccination groups at 16 months of 
age were the group of children without DTP or MMR 
(labelled ‘None’) and the group of children with MMR 
only. At baseline, the two groups represented 1.67% and 
0.14% of the cohort, respectively, and were not of primary 
interest. The children with no vaccinations had a lower 
estimated hazard of hospitalisation for infection and onset 
of asthma. The characteristics of this group were peculiar. 
For example, 98.09% of the children with a missing value 
of the ethnicity variable (462 of 471) had no vaccinations 
at 16 months age, which was extreme bearing in mind 
that these children only constituted 1.67% of the cohort. 
Information available on request and is given in online 
supplementary tables S5 and S6.
The result of adjustment
The largest differences between the crude HR and aHRs 
were found in the mortality outcome. In particular, the 
mortality estimates corresponding to the 1 and 2 DTP 
groups were largely reduced after adjustment. However, 
the HR corresponding to the group of children with no 
vaccinations (the None group) also changed somewhat 
after adjustment in the outcomes hospitalisation for 
infection and onset of asthma. This suggests that some of 
the peculiarity in the composition of the None-group was 
captured by the differences in the observed confounder 
distributions.
Alternative parametrisation
The results presented in table 3 are based on analysis with 
one exposure variable with eight levels—the four times 
two combinations of DTP and MMR. Alternatively one 
could define two separate variables with four levels, DTP 
∈ {0, 1, 2, 3}, respectively two levels, MMR ∈ {0, 1}, and 
study their interaction. The result of such an analysis is 
presented in online supplementary table S8.
Absolute risks
The absolute risk is the probability of experiencing 
the outcome. The vaccination-specific absolute risks of 
experiencing the main outcomes were calculated from 
16, 20, 24, 36 and 48 months until 5 years of age, and 
as explained in the Methods section, these are the time 
points at which the vaccination status exposure is re-eval-
uated. The results from the landmark time points of 16 
months and 36 months (3 years) of age are presented in 
table 4. Here the relative risks are ratios between two abso-
lute risks. The number of deaths diminished toward the 
end of follow-up making the mortality estimates uncer-
tain. The landmark results from 20, 24 and 48 months 
of age can be found in the online supplementary table 
S9, where the vaccination-specific results corresponding 
to the two groups without DTP (None and MMR) are also 
presented (online supplementary table S10).
Based on the 95% CIs, the mortality risks of the 3DTP 
and 3DTP+MMR groups appear similar. This differs from 
the result of the cause-specific hazards analysis. One 
notable difference between the interpretations is that 
the landmark analysis from 16 months of age does not 
consider children who are vaccinated with MMR more 
than 1 month later than scheduled. For all vaccination 
groups at all landmark times, the absolute risk of dying was 
negligible. Otherwise the relative risks are close to 1 indi-
cating that for these outcomes the different vaccination 
regimens had no clinically important impact on the risks: 
no matter the vaccination status at 16 months of age, the 
risk of experiencing a hospitalisation for infection before 
5 years of age was around 16%, and the risk of asthma was 
around 10%. For the event-free children surviving up to 3 
years of age, the risks were around 5% for hospitalisation 
for infection and around 2% for asthma.
negative control outcome: examining residual confounding
The absolute risks estimated using the g-formula repre-
sent average causal effects if there are no unmeasured 
confounders. To investigate this assumption, the nega-
tive control outcome ‘hospitalisations related to acci-
dents’ was analysed and the results of the cause-specific 
Cox regression model with this outcome are presented 
in table 5.
Children with 1 or 2 DTP only were found to have 
similar hazards of being hospitalised due to accidents 
than that of the reference group of children with 3 DTP: 
aHR=1.09 (95% CI: 1.00 to 1.19) and aHR=1.05 (95% CI: 
0.99 to 1.11).
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Table 4 For each of the two outcomes: hospitalisation for infection (middle part of table) and asthma (lower part of table): 5 
years of age absolute and relative risks (3DTP as reference) are presented by vaccination status (apart from the two groups 
without DTP) at landmark times 16 and 36 months of age (with 95% Wald CIs). For the mortality outcome (upper part of table), 
only relative risks are presented (all absolute mortality risks <0.001)
Vaccination status 
compared with 3DTP Risk measure 16 months 3 years
Mortality-relative risks up to 5 years of age
  1DTP Relative risk 1.89 (1.72 to 2.06) 1.34 (0.77 to 1.90)
  2DTP Relative risk 1.40 (1.24 to 1.56) 0.86 (0.07 to 1.65)
  1DTP+MMR Relative risk 0.47 (0.01 to 2.82) 0.28 (0.00 to 4.62)
  2DTP+MMR Relative risk 0.93 (0.55 to 1.32) 0.59 (0.00 to 1.46)
  3DTP+MMR Relative risk 0.75 (0.47 to 1.02) 0.45 (0.00 to 1.37)
Vaccination status Risk measure 16 months 3 years
Hospitalisation for infection—absolute and relative risks up to 5 years of age
  3DTP* Absolute risk 0.166 (0.165 to 0.168) 0.056 (0.054 to 0.058)
  1DTP Absolute risk
Relative risk
0.173 (0.169 to 0.178)
1.04 (1.02 to 1.07)
0.052 (0.047 to 0.057)
0.92 (0.81 to 1.03)
  2DTP Absolute risk
Relative risk
0.172 (0.170 to 0.174)
1.03 (1.02 to 1.04)
0.053 (0.050 to 0.056)
0.93 (0.86 to 1.00)
  1DTP+MMR Absolute risk
Relative risk
0.167 (0.161 to 0.174)
1.01 (0.97 to 1.05)
0.052 (0.049 to 0.055)
0.92 (0.85 to 0.99)
  2DTP+MMR Absolute risk
Relative risk
0.163 (0.160 to 0.166)
0.98 (0.96 to 1.00)
0.055 (0.053 to 0.056)
0.97 (0.93 to 1.01)
  3DTP+MMR Absolute risk
Relative risk
0.161 (0.159 to 0.162)
0.96 (0.95 to 0.97)
0.053 (0.053 to 0.054)
0.95 (0.91 to 0.98)
Asthma—absolute and relative risks up to 5 years of age
  3DTP* Absolute risk 0.106 (0.105 to 0.107) 0.024 (0.023 to 0.025)
  1DTP Absolute risk
Relative risk
0.101 (0.098 to 0.104)
0.95 (0.92 to 0.98)
0.023 (0.02 to 0.026)
0.95 (0.79 to 1.11)
  2DTP Absolute risk
Relative risk
0.105 (0.103 to 0.106)
0.99 (0.97 to 1.01)
0.024 (0.022 to 0.027)
1.01 (0.92 to 1.11)
  1DTP+MMR Absolute risk
Relative risk
0.111 (0.106 to 0.116)
1.05 (1.00 to 1.09)
0.025 (0.023 to 0.027)
1.05 (0.95 to 1.14)
  2DTP+MMR Absolute risk
Relative risk
0.105 (0.103 to 0.107)
0.99 (0.97 to 1.01)
0.025 (0.024 to 0.026)
1.04 (0.98 to 1.10)
  3DTP+MMR Absolute risk
Relative risk
0.104 (0.103 to 0.104)
0.98 (0.96 to 0.99)
0.024 (0.024 to 0.024)
1.00 (0.94 to 1.05)
*The reference group is 3DTP.
DTP, diphteria–tetanus–pertussis–polio–Haemophilus influenzae type b; MMR, measles–mumps–rubella.
Children with 3 DTP+MMR were found to have a lower 
hazard of being hospitalised due to accidents compared 
with that of the 3 DTP group: aHR=0.83 (95% CI: 0.80 to 
0.85). The hazards of children with 1, 2 or 3 DTP+MMR 
were similar based on the CIs.
Thus, the results of the negative control outcome anal-
ysis suggest that the mechanisms explaining exposure to 
MMR remain partly uncontrolled for.
DISCuSSIOn
Findings
This national cohort study of more than 1.12 million 
Danish children aimed at estimating the association 
between early childhood vaccination and subsequent 
mortality and morbidity. The study found an association 
between MMR and reduced mortality, but no detrimental 
effect of DTP. However, the study also found an associa-
tion between MMR and hospitalisation for accidents indi-
cating residual confounding, so-called ‘healthy vaccinee 
bias’.
Many children did not receive MMR by 16 months of age. 
In Denmark, it is well-known than parents tend to forget/
postpone the MMR vaccine scheduled at 15 months of 
age to a larger degree than it is the case for the 3 DTP 
vaccines at 3, 5 and 12 months of age. Usually parental 
leave lasts 12 months in Denmark covering the timing of 
the DTP vaccines, but not the MMR. When children enter 
daycare, their risk of infection and fever increases which 
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Table 5 Crude and adjusted HRs for the negative control 
outcome. The estimated parameters were HRs. The 
reference group was the group of children with 3DTP, but no 
MMR
Outcome Hospitalisation due to accidents
Group compared 
with 3DTP Crude HR (95% CI) Adjusted HR (95% CI)
1DTP 1.12 (1.03 to 1.22) 1.09 (1.00 to 1.19)
2DTP 1.07 (1.01 to 1.13) 1.05 (0.99 to 1.11)
1DTP+MMR 0.83 (0.77 to 0.89) 0.84 (0.79 to 0.91)
2DTP+MMR 0.83 (0.79 to 0.86) 0.84 (0.80 to 0.87)
3DTP+MMR 0.81 (0.78 to 0.83) 0.83 (0.80 to 0.85)
None 0.83 (0.76 to 0.91) 0.92 (0.84 to 1.01)
MMR 0.96 (0.82 to 1.12) 0.86 (0.27 to 2.74)
DTP, diphteria–tetanus–pertussis–polio–Haemophilus influenzae type 
b; MMR, measles–mumps–rubella.
again tends to postpone the date of vaccination. In the 
landmark approaches any postponed uptake before the 
given landmark time point was accounted for.
Strengths and weaknesses
The strengths of the present study include the large 
sample size, the national cohort study design, the inclu-
sion of all combinations of vaccines, estimation of 
absolute risks, the flexibility of the time-dependent vacci-
nation exposure status and the negative control outcome 
of hospitalisation due to accidents which cannot readily 
be pathogenetically related to the vaccine exposure. In 
the present study, we elaborated on the analytical strategy 
of a recent study from the Netherlands.7 Here the authors 
claimed to have found that the decreased risk of adverse 
health outcomes was associated with receipt of any addi-
tional vaccine and not specifically the live-attenuated 
MMR vaccine. However, in that study only children with 
at least 3 or 4 DTP vaccinations were included in the 
analysis, while the present study extensively examined 
all combinations of early childhood vaccines adminis-
tered according to the Danish vaccination programme. 
We broadened the comparison groups by not restricting 
the population to children who received at least 3 DTP 
vaccinations.7 This enabled the observation of decreased 
mortality with an increased number of DTP vaccines in 
the absence of MMR.
One weakness of all observational studies is the possi-
bility of unmeasured confounding. It is not known whether 
further adjustment for relevant confounders would 
change the estimated HRs, but the association between 
MMR and hospitalisation due to accidents indicates a 
problem with the confounder control. The unmeasured 
confounders could include medication administered in 
hospital which is not measurable on an individual level 
in the Danish national health registries, immunodefi-
ciencies and other severe chronic diseases not captured 
by our definition of chronic disease, and other measures 
of somatic frailty which are hard to identify. In addition, 
several social aspects and family resources which are hard 
to capture in the national registries could influence the 
results.
Other weaknesses include potential misclassifications 
of exposure or outcome status and other variables used in 
the analyses. Regarding misclassification of the vaccina-
tion status, the misclassification in reimbursement-based 
register data is likely to be minimal due to financial 
incentives for the general practitioners who administer 
the vaccines, and whenever present any misclassification 
is most likely non-differential, that is, individuals were 
misclassified with equal probability across all groups 
in the study. Regarding misclassification of outcomes: 
mortality information is reliable, whereas hospitalisa-
tions and asthma can be prone to misclassification. The 
former only to a small extent since it is in the interest 
of the hospital department that the diagnoses are coded 
correctly to obtain reimbursement. Asthma is not ascer-
tained without error as seen in our previous validation 
study of the algorithm defining asthma.
note on the children with no vaccines
The children without any vaccines at 16 months of 
age constitute a small subgroup (1.67 %) which is not 
representative of the general population. In fact, a lot 
of these ill children might have been vaccinated on the 
hospital and not by the general practitioner—and this 
study is based on information from the latter. The very 
fact that these children were possibly vaccinated at the 
hospital suggest that they represent a very ill subgroup. 
The frequency of missing data in this among these chil-
dren (online supplementary table S5) can be due to 
their complicated births: typically, the midwife ascertains 
the information after birth, but this procedure has low 
priority in these few, severe cases. These children barely 
use the remaining health system and have few incident 
hospitalisations for infections since they might already 
be hospitalised, or they are hospitalised for even more 
severe reasons, and thus having no vaccines appears bene-
ficial when the outcome is ascertained by register-based 
non-mortality outcomes. But they die a lot earlier than 
the remaining population.
Comparison with other studies
Since the negative control outcome, as already mentioned, 
points toward residual confounding, our study also 
suggests that residual confounding may have been 
present in previous Danish register-based studies inves-
tigating the impact of MMR on the morbidity outcomes 
respiratory syncytial virus and hospitalisation for infection 
until 2 years of age3 4 and asthma-like disease until 5 years 
of age.5 A previous study found no association between 
MMR and the rate of emergency room visits.6
The estimated HR for mortality after administration 
of MMR seems large. However, effect sizes of this magni-
tude are in line with prior estimates2; based on this it is 
not uncommon to estimate halved mortality hazards. As 
for all estimates in the present study and prior studies, 
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this HR may be prone to biases from sources similar to 
the ones discussed under the section Note on children 
with no vaccines above: some children who do not receive 
MMR suffer from disease such as immunodeficiencies 
and socioeconomic disadvantages which again affect the 
analysed outcomes.
Meaning of study, explanations and implications
The study points at reduced mortality after MMR vacci-
nation, but any additional DTP vaccination was not asso-
ciated with increased mortality; in fact, any additional 
vaccination with DTP even seemed to be associated with 
reduced mortality in the group of children without MMR. 
No clinically important differences between vaccination 
groups were found for the outcomes hospitalisation for 
infection and asthma even though an increased hazard 
of asthma with the number of DTP vaccinations was 
estimated.
unanswered questions and future research
Based on the results, we raise the question if the lower risk 
of mortality in children with MMR may to some degree be 
explained by unobserved confounding by, for example, 
contraindication of live-attenuated vaccines in immuno-
compromised individuals with a very high risk of adverse 
health events which was not appropriately adjusted for 
even after the inclusion of the 12 relevant confounders. 
Therefore, non-specific effects of vaccines are best exam-
ined in randomised trials.
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